It has also been reported that treatment with the pan-VEGF receptor tyrosine kinase inhibitor, cediranib, leads to an increase in tumor infiltration along the pre-existing brain vessels, both in animal models [37] and human GBM patient biopsies [46]. This evidence concerns the gene VEGFA and neoplasm.